Achillion to begin Phase IIa of ACH-4471 in C3 glomerulopathy

This half, Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) expects to begin a Phase IIa trial of ACH-4471 for 14 days in about 10 patients with low levels of complement 3 (C3) due to C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis.

The primary endpoint of the open-label, Australian trial is the change from baseline to day 21 in C3 levels. Secondary endpoints include safety, pharmacokinetics and biomarkers...